Gossamer Bio, Inc.

GOSS
$0.17 (+ $0.00 + 2.98%)
Last updated: 2026-07-04 15:30 UTC
GOSS Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS38341P1021
CUSIP38341P102
Market Price0.17
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.69
Market Cap$796.2M
Book Value-0.36
Price to Book-9.663
Beta1.92
52w High3.87
52w Low0.76
Next Earnings DateN/A

Gossamer Bio, Inc. trades under ticker GOSS on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US38341P1021, CUSIP 38341P102.

About the Company
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Price History